Skip to main
AIM

AIM Stock Forecast & Price Target

AIM Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AIM ImmunoTech has demonstrated a robust pipeline with positive initial data from its Phase 2 studies, particularly regarding Ampligen's application in both post-COVID conditions and as part of a chemokine modulatory regimen for metastatic colorectal cancer. These results not only validate the efficacy of Ampligen but also position the company favorably within the immuno-pharmaceutical market, addressing significant unmet medical needs. Furthermore, the continual release of strong positive data is expected to serve as a catalyst for potential stock growth as investor confidence is bolstered by these developments.

Bears say

AIM ImmunoTech reported a net loss of $3.3 million, with earnings per share (EPS) of $(1.57), significantly underperforming both the company’s and consensus estimates. The firm's ongoing financial challenges are compounded by a reliance on the success of its product candidates, with risks including potential failures in clinical trials, regulatory approvals, and commercialization efforts. Additionally, external factors such as liquidity risks, competition, and shifting investor sentiment towards biotech stocks heighten the uncertainty surrounding AIM ImmunoTech's financial outlook.

AIM has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AIM ImmunoTech Inc (AIM) Forecast

Analysts have given AIM a Strong Buy based on their latest research and market trends.

According to 1 analysts, AIM has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AIM ImmunoTech Inc (AIM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.